VERY EARLY MOLECULAR RESPONSE (VEMR) WITH FRONTLINE DASATINIB TREATMENT IS A STRONG PREDICTOR OF LONG-TERM BCR-ABL1 TRANSCRIPT LEVELS IN CHRONIC MYELOID LEUKEMIA PATIENTS: PCR-DEPTH STUDY
2018
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI